- Home
- JBDI vs CURX Comparison
JBDI vs CURX Comparison
Compare JBDI & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JBDI | CURX |
|---|---|---|
| Founded | 1983 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 7.8M |
| IPO Year | 2023 | 2024 |
Fundamental Metrics
Financial Performance| Metric | JBDI | CURX |
|---|---|---|
| Price | $2.36 | $5.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.4M | 20.3K |
| Earning Date | 10-15-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.21 |
| 52 Week High | $9.50 | $13.80 |
Technical Indicators
Market Signals| Indicator | JBDI | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 58.81 | 59.08 |
| Support Level | $0.79 | $5.24 |
| Resistance Level | $9.50 | $6.00 |
| Average True Range (ATR) | 0.93 | 0.44 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 4.79 | 78.57 |
Price Performance
Historical ComparisonAbout JBDI JBDI Holdings Limited Ordinary Shares
JBDI Holdings Ltd, through its subsidiaries, is mainly engaged in the reconditioning and recycling of containers in Singapore. Its products include reconditioned and new steel drums, plastic drums, carboys, and IBCs with different capacities, and its customers span various industries such as the solvent, chemical, petroleum, and edible oil industries. Additionally, the Group offers ancillary services, such as reconditioning services, wastewater equipment services, and sales of recycled materials and services to complement its core business. The majority of its revenue is derived from the sale of reconditioned containers. Geographically, the Group derives all its revenue from Singapore.
About CURX Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout. Phyto-N, is a proprietary botanical extract with chemical components and pharmacological activities that harnesses potential anti-inflammatory properties of a medicinal plant.